“…We showed that the inclusion of riluzole, an inhibitor of glutamate export, and/or CB-839, an inhibitor of glutaminase, in the growth media led to a reduction in cell growth and subsequent tumor progression in vitro and in vivo [ 39 , 68 ]. The application of riluzole has shown promise in melanoma, breast cancer, glioma, prostate cancer, and kidney cancer [ 39 , 89 , 97 , 101 , 119 , 121 , 177 , 178 , 179 ]. Our lab and others have provided pre-clinical data that support the combination of riluzole/troriluzole with different therapeutic approaches that target different oncogenic pathways: oxidative stress/genomic instability (γ-radiation therapy or PARP inhibitors), cell metabolism (CB-839), and angiogenesis/metastasis (anti-VEGF treatments or inhibitors for exosome biogenesis and secretion) [ 28 , 57 , 68 , 69 , 119 , 178 , 179 , 180 , 181 , 182 , 183 ].…”